)
)
)
NeuroCores, Inc.
Please kindly note that we are not meeting with service providers during the conference. Thank you.
NeuroCores is a preclinical biotech company developing first in class plasmalogen derivative drugs for rare pediatric neurodevelopmental disorders and neurodegenerative diseases. The company's lead asset is KIT-13, an oral small molecule drug for treating Rett Syndrome. KIT-13 has been granted both RPDD (Rare pediatric disease designation) and ODD (Orphan drug designation) for treating Rett syndrome by the US FDA.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)